Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed FCF Margin for 5 consecutive years, with 73.62% as the latest value for Q2 2024.

  • Quarterly FCF Margin rose 243192.0% to 73.62% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 9.45% through Mar 2025, up 369829.0% year-over-year, with the annual reading at 3.12% for FY2024, 325795.0% up from the prior year.
  • FCF Margin for Q2 2024 was 73.62% at Fulcrum Therapeutics, up from 2717.11% in the prior quarter.
  • The five-year high for FCF Margin was 73.62% in Q2 2024, with the low at 8201.69% in Q1 2023.
  • Average FCF Margin over 5 years is 1691.08%, with a median of 862.35% recorded in 2022.
  • The sharpest move saw FCF Margin tumbled -733935bps in 2023, then skyrocketed 243192bps in 2024.
  • Over 5 years, FCF Margin stood at 480.43% in 2020, then grew by 15bps to 409.27% in 2021, then plummeted by -538bps to 2609.49% in 2022, then decreased by -4bps to 2717.11% in 2023, then surged by 103bps to 73.62% in 2024.
  • According to Business Quant data, FCF Margin over the past three periods came in at 73.62%, 2717.11%, and 3011.73% for Q2 2024, Q4 2023, and Q3 2023 respectively.